Excision BioTherapeutics, a Philadelphia, PA-based life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by neurotropic viruses, completed a $10m seed financing.
The round was led by ARTIS Ventures.
The company intends to use the funds to enter into human clinical trials with its HIV-1 targeted CRISPR platform, giving it the first effort to fully remove/excise the HIV-1 genome from all human cells and tissues, as well as to extend this approach to other viruses by targeting their genetic elements, and eliminating them permanently from the patient.
Led by Thomas Malcolm, Ph.D, founder, president and CEO, Excision BioTherapeutics focuses on the development and commercialization of advanced gene editing therapeutics for the treatment and eradication of life-threatening disease caused by neurotropic viruses (viral infections).
The company was founded in 2015 out of Temple University’s Lewis Katz School of Medicine in Philadelphia, PA.
Company founders include Kamel Khalili, Ph.D., Thomas Malcolm, Ph.D., Rob Simmons, and David Rowe.